PubMed COVID-19 Clinical Care

A psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: a single-masked, phase 3, superiority, randomised controlled trial

Sunday, February 04, 2024 - 4:00 AM

BACKGROUND: Although national guidelines recommend that everyone with dementia receives personalised post-diagnostic support, few do. Unlike previous interventions that improved personalised outcomes in people with dementia, the NIDUS-Family

Maximizing scarce colonoscopy resources: the crucial role of Stool-Based tests

Sunday, February 04, 2024 - 4:00 AM

During the COVID-19 pandemic, health systems, including federally qualified health centers (FQHCs), experienced disruptions in colorectal cancer (CRC) screening. National organizations called for greater use of at-home stool-based testing followed by

Anti-N-methyl D-aspartate Receptor Encephalitis Following ChAdOx1 nCoV-19 Vaccination: A Case Report

Sunday, February 04, 2024 - 4:00 AM

As of December 2020, millions of people have been immunized using vaccines against SARS-CoV-2. A wide range of neurological adverse effects of SARS-CoV-2 vaccines have been reported so far. Here, we report a 23-year-old male who experienced

Antibody responses to SARS-CoV-2 vaccines in neuromuscular disorders may depend on their etiology and current drug treatment

Sunday, February 04, 2024 - 4:00 AM

No abstract

Structural Basis for coronaviral main proteases Inhibition by a 3CL Protease Inhibitor- GC376

Sunday, February 04, 2024 - 4:00 AM

The main protease (M^(pro)) of coronaviruses participates in viral replication, serving as a hot target for drug design. GC376 is able to effectively inhibit the activity of M^(pro), which is due to nucleophilic addition of GC376 by binding

PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial

Sunday, February 04, 2024 - 4:00 AM

BACKGROUND: Currently available injectable drugs that target proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular outcomes. This phase 2 study assessed NNC0385-0434, an oral PCSK9 inhibitor, in

Results from the SARS-CoV-2 wastewater-based surveillance system in Denmark, July 2021 to June 2022

Sunday, February 04, 2024 - 4:00 AM

The microbiological analysis of wastewater samples is increasingly used for the surveillance of SARS-CoV-2 globally. We described the setup process of the national SARS-CoV-2 wastewater-based surveillance system in Denmark, presented its main results

An interdisciplinary course on computer-aided drug discovery to broaden student participation in original scientific research

Saturday, February 03, 2024 - 4:00 AM

We present a new highly interdisciplinary course in computer-aided drug discovery (CADD). This course was developed in response to a call for alternative pedagogical approaches during the COVID-19 pandemic, which caused the cancellation of a face-to

CCL18, CHI3L1, ANG2, IL-6 systemic levels are associated with the extent of lung damage and radiomic features in SARS-CoV-2 infection

Saturday, February 03, 2024 - 4:00 AM

CONCLUSION: Data suggest a causal link between cytokines (risk factor), lung damage (mediator), and COVID-19 outcomes.

Insomnia is more likely to persist than remit after a time of stress and uncertainty: A longitudinal cohort study examining trajectories and predictors of insomnia symptoms

Saturday, February 03, 2024 - 4:00 AM

CONCLUSIONS: Insomnia was more likely to persist than remit over the first year of the COVID-19 pandemic. Addressing sleep reactivity and sleep effort appears critical for reducing insomnia persistence rates after times of stress and uncertainty.